Cyclophosphamide-prednisolone therapy in advanced prostatic carcinoma.
Cyclophosphamide and prednisolone therapy was given to 83 patients with hormone-resistant disseminated carcinoma of the prostate. In 7 cases there were objective signs of regression of metastases. Significant reduction of elevated acid phosphatase activity was recorded in 11 cases, in 2 of them to normal range. 55 patients experienced pain relief, 26 of them very good. In the majority of cases duration of the remission was shorter than 6 months, in 2 cases it lasted more than a year.
D000135:Acid Phosphatase / Q000097:blood; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis; D011239:Prednisolone / Q000009:adverse effects / Q000627:therapeutic use*; D011471:Prostatic Neoplasms / Q000188:drug therapy*
D003520:Cyclophosphamide; D011239:Prednisolone; D000135:Acid Phosphatase